Daniela Boggiani

Parma, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.

Journal: NPJ breast cancer

Published: July 31, 2025

SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy.

SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy.

Journal: Cancers

Published: March 13, 2025

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents.

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents.

Journal: ESMO open

Published: February 12, 2024

Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing.

Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing.

Journal: Genes

Published: December 30, 2023

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: March 21, 2022

Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers.

Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers.

Journal: Frontiers in oncology

Published: April 27, 2021

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Journal: ESMO open

Published: October 25, 2020

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.

Journal: Cancers

Published: March 23, 2020

Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer.

Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer.

Journal: Critical reviews in oncology/hematology

Published: May 24, 2019

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.

Journal: Frontiers in oncology

Published: April 27, 2019

Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors.

Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors.

Journal: JAMA oncology

Published: October 04, 2017

Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.

Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 29, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026